With the Federal Reserve sounding more cautious on interest rate hikes as growth cools and inflation drifts lower, small-cap stocks are back under the spotlight for investors who want exposure to potential shifts in market sentiment without ignoring risk. The screener behind this article focuses on smaller companies with market caps between $400 million and $1,000 million that combine relatively stronger financial health with sensitivity to changing rate expectations. Below, you will find three small-cap stocks that stand out as positively exposed to the current Fed pause debate, helping you evaluate which ideas may deserve a closer look.

PolyNovo (ASX:PNV)

Overview: PolyNovo is a medical device company that develops and sells biodegradable NovoSorb-based products used to help regenerate skin and soft tissue after severe burns, trauma, or complex surgery. It is also building a pipeline in hernia repair, chronic wounds, plastics and reconstructive procedures. The company operates across Australia, New Zealand, the United States, Europe and parts of Asia, supplying hospitals and surgeons with specialist wound care and reconstructive solutions.

Operations: PolyNovo generates essentially all of its A$139.5m in revenue from the development, manufacturing and commercialisation of its NovoSorb technology, with the United States contributing A$104.1m, other countries A$24.8m, and Australia and New Zealand A$9.0m.

Market Cap: A$635.6m

For investors watching how a potential Fed pause could influence appetite for quality small caps, PolyNovo stands out as a medical device company with expanding international sales and a focused technology platform that is already generating recurring revenue. The combination of trading below some fair value estimates and fresh R&D leadership through the appointment of a new Chief Scientific Officer is attracting attention, but the company is also exposed to regulatory decisions, reimbursement shifts in key markets and reliance on NovoSorb for much of its future. How those ambitions, valuation signals and risk factors fit together is where the real story starts.

PolyNovo’s expanding NovoSorb footprint and recurring revenue story can look compelling, but the real tension is how much is already priced in. Line up the growth ambitions against the DCF valuation analysis for PolyNovo to see what the market might be missing.

Delcath Systems (DCTH)

Overview: Delcath Systems is an interventional oncology company focused on treating primary and metastatic liver cancers, using its HEPZATO KIT and CHEMOSAT systems to deliver high-dose chemotherapy directly to the liver while limiting exposure to the rest of the body across the United States and Europe.

Operations: Delcath Systems generates about US$90.4m in revenue from the research, development, manufacture and distribution of its hepatic delivery systems, with approximately US$84.1m from the United States and US$6.4m from foreign markets.

Market Cap: US$447.1m

Delcath Systems sits at the intersection of specialist cancer care and the small-cap theme investors are watching as the Fed talks more openly about pausing rate hikes. It combines a focused liver cancer platform with forecasts for double digit revenue and earnings growth. HEPZATO KIT and CHEMOSAT are gaining clinical recognition through inclusion in major guidelines and new trial data, while index additions to several Russell benchmarks may increase visibility among institutional investors if small caps come back into favor. At the same time, heavy dependence on a single therapy, pricing pressure from access programs and a recent quarterly net loss highlight why funding and execution still matter. How those growth ambitions balance against the risks and current valuation is where Delcath’s story becomes more interesting.

Delcath Systems sits where clinical recognition, fresh trial data and index inclusion are starting to converge, yet the share price story still feels incomplete. See how the analyst forecasts for Delcath Systems stack up against execution risk and what the market might be glossing over next.

Jumia Technologies (JMIA)

Overview: Jumia Technologies runs an e-commerce platform focused on Africa, connecting consumers and businesses to a wide range of products and services, from phones and electronics to groceries, supported by its own logistics network and digital payments infrastructure under the Jumia brand.

Operations: Jumia Technologies generates about US$203.2m in revenue from its e-commerce platform.

Market Cap: US$816.2m

Jumia Technologies sits at the intersection of Africa’s growing online retail market and global risk appetite for emerging market small caps. These can benefit when Fed policy tilts more dovish and funding conditions ease. The company is still reporting losses and carries higher funding risk because it relies on external sources rather than customer deposits. Earnings have grown quickly over the past 5 years and analysts expect a shift toward profitability over the next few years. The stock trades below some fair value estimates even as its P/S multiple is higher than many peers. This reflects a mix of optimism and caution. How those growth expectations, valuation signals and governance concerns fit together is where the opportunity, and the real debate, begins.

Jumia Technologies is where fast growing e-commerce adoption meets a stock that still carries funding and governance questions, so line up that tension against the analyst forecasts for Jumia Technologies to see what might be quietly reshaping the story

The three stocks in this article are just a starting point, and the full screener uncovered 36 more small-cap companies with equally compelling narratives that you may want to put on your radar through the Small-Cap Stocks screener. Use Simply Wall St to identify, filter and analyze the specific catalysts and storylines that matter to you so you can focus on the highest conviction small-cap ideas that fit your approach.

Take Control of Your Investment Journey

If PolyNovo or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond These Picks?

Small caps can move quickly, and newer stories may not stay under the radar for long. Explore these curated ideas before the next potential breakout wave is captured.

• Identify income-oriented companies with steady cash flows and strong coverage by running through the 5 dividend fortresses before yields start dropping as more investors take notice.
• Look for early momentum in fast growing companies with clean finances by scanning the curated 12 high quality undiscovered gems while they remain less widely followed.
• Review the hand picked 35 power grid technology and infrastructure stocks to research companies involved in grid technology ahead of potential future infrastructure upgrade cycles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.